(Q35842986)

English

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial

scientific article published on 6 March 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial (English)

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

20

object named as

Giuseppe Viale

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

12

object named as

Patrick Neven

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

4

object named as

Olivia Pagani

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Aron Goldhirsch

18

object named as

Aron Goldhirsch

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Meredith M Regan

1

object named as

Meredith M Regan

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

15

object named as

Karen N Price

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Roswitha Kammler

6

object named as

Roswitha Kammler

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Henrik J. Ditzel

11

object named as

Henrik J Ditzel

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

13

object named as

Marc Debled

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

19

object named as

James M Rae

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Beat Thürlimann

9

object named as

Beat Thürlimann

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

author name string

Brian Leyland-Jones

2

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Mark Bouzyk

3

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Weining Tang

5

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Patrizia Dell'orto

7

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Maria Olivia Biasi

8

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Maria B Lyng

10

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Rudolf Maibach

14

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Richard D Gelber

16

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Alan S Coates

17

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Breast International Group (BIG) 1-98 Collaborative Group

21

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

language of work or name

0 references

publication date

6 March 2012

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Journal of the National Cancer Institute

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

104

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

6

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

441-451

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

11 July 2018

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

11 July 2018

Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

11 July 2018

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

11 July 2018

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

11 July 2018

Pharmacogenetics of endocrine therapy for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

11 July 2018

Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

11 July 2018

High-efficiency genotype analysis from formalin-fixed, paraffin-embedded tumor tissues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

11 July 2018

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

11 July 2018

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

11 July 2018

Pharmacogenomics of tamoxifen therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

11 July 2018

Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

11 July 2018

The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

11 July 2018

Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

11 July 2018

Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

11 July 2018

Tamoxifen, hot flashes and recurrence in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

11 July 2018

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

11 July 2018

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

11 July 2018

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

11 July 2018

Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

11 July 2018

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

11 July 2018

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

11 July 2018

Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

11 July 2018

Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

11 July 2018

Metabolites of tamoxifen in animals and man: Identification, pharmacology, and significance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

11 July 2018

Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

24 September 2018

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

24 September 2018

Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

24 September 2018

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

24 September 2018

Polymorphism in the CYP2D6 Tamoxifen-Metabolizing Gene Influences Clinical Effect but Not Hot Flashes: Data From the Italian Tamoxifen Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3309132

14 November 2018

Reporting recommendations for tumor marker prognostic studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/22395644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/22395644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

1 reference

https://pubmed.ncbi.nlm.nih.gov/22395644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system

1 reference

https://pubmed.ncbi.nlm.nih.gov/22395644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Impact of CYP2D6 Genotyping on Tamoxifen Treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/22395644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/JNCI/DJS125

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35842986&oldid=1966930363"